Ambient

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.

Suppression of Tumorigenicity 2 (ST2), a member of the Interleukin-1 receptor family, has two isoforms, one is soluble form (sST2) and the other one is transmembrane form (ST2L). sST2, lacking the transmembrane and intracellular domains, can prevent the interaction between IL-33 and ST2L. It plays a role in inflammatory and immune processes and is considered as a promising marker for myocardial stress.